Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk

Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its experimental obesity pill.

Previous post A Trump White House could see M&A uptick in these sectors
Next post Foreign buyers are fleeing the U.S. housing market, with sales at a record low